Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 1 for:    study of hydroxychloroquine in combination with FOLFOX plus bevacizumab to inhibit autophagy in colorectal cancer
Previous Study | Return to List | Next Study

FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2013 by Abramson Cancer Center of the University of Pennsylvania.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT01206530
First received: September 16, 2010
Last updated: February 25, 2013
Last verified: February 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2013
  Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)